Technical Analysis for MDWD - MediWound Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 16.78 | 6.20% | 0.98 |
MDWD closed up 6.2 percent on Wednesday, November 20, 2024, on 1.93 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Flat | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | 6.20% | |
Earnings Movers | Other | 6.20% | |
Gapped Up | Strength | 6.20% | |
Oversold Stochastic | Weakness | 6.20% | |
Lower Bollinger Band Walk | Weakness | 7.29% | |
Below Lower BB | Weakness | 7.29% |
Alert | Time |
---|---|
Gapped Up (Partial) | about 21 hours ago |
Rose Above Previous Day's High | about 21 hours ago |
10 DMA Resistance | about 21 hours ago |
2x Volume Pace | about 21 hours ago |
1.5x Volume Pace | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/19/2024
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, and connective tissue disorders. Its lead product candidate is EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Wound Acute Pain Burns Connective Tissue Medical Emergencies Necrosis Yavne
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Wound Acute Pain Burns Connective Tissue Medical Emergencies Necrosis Yavne
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.0 |
52 Week Low | 8.41 |
Average Volume | 40,408 |
200-Day Moving Average | 16.84 |
50-Day Moving Average | 17.25 |
20-Day Moving Average | 17.22 |
10-Day Moving Average | 16.56 |
Average True Range | 0.73 |
RSI (14) | 47.64 |
ADX | 20.79 |
+DI | 15.14 |
-DI | 20.77 |
Chandelier Exit (Long, 3 ATRs) | 16.24 |
Chandelier Exit (Short, 3 ATRs) | 17.71 |
Upper Bollinger Bands | 18.89 |
Lower Bollinger Band | 15.55 |
Percent B (%b) | 0.37 |
BandWidth | 19.37 |
MACD Line | -0.34 |
MACD Signal Line | -0.19 |
MACD Histogram | -0.1509 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.36 | ||||
Resistance 3 (R3) | 18.20 | 17.53 | 18.09 | ||
Resistance 2 (R2) | 17.53 | 17.13 | 17.60 | 18.00 | |
Resistance 1 (R1) | 17.15 | 16.88 | 17.34 | 17.31 | 17.92 |
Pivot Point | 16.48 | 16.48 | 16.57 | 16.55 | 16.48 |
Support 1 (S1) | 16.10 | 16.08 | 16.29 | 16.26 | 15.64 |
Support 2 (S2) | 15.43 | 15.83 | 15.50 | 15.56 | |
Support 3 (S3) | 15.05 | 15.43 | 15.47 | ||
Support 4 (S4) | 15.21 |